# TLR2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - TLR2 is a transmembrane glycoprotein that functions as a pattern recognition receptor, crucial for detecting pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) through heterodimerization with TLR1 or TLR6. - Its signaling cascade is primarily MyD88-dependent, leading to the activation of NF-κB and MAPK pathways, which drive the transcription of pro-inflammatory cytokines and chemokines. - Polymorphisms in the *TLR2* gene, notably Arg753Gln (rs5743708) and rs3804099, are associated with increased susceptibility to infectious diseases such as tuberculosis and inflammatory conditions like periodontitis. - TLR2 plays a significant role in host-pathogen interactions, recognizing components from bacteria (e.g., lipoteichoic acid, peptidoglycan), viruses (e.g., RV VP4 protein), fungi (e.g., zymosan), and parasites, as well as endogenous DAMPs like HMGB1. - Therapeutic strategies targeting TLR2 are under investigation, including small-molecule inhibitors (e.g., C29, CU-CPT22) and monoclonal antibodies (e.g., OPN-305), alongside its use as a vaccine adjuvant (e.g., Pam3CSK4). --- ## Executive Summary & Key Metadata Toll-like Receptor 2 (TLR2) is a germline-encoded pattern recognition receptor (PRR) of the innate immune system, critical for the detection of conserved molecular structures known as pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). As a type I transmembrane glycoprotein, TLR2 is unique among TLRs due to its ability to form functional heterodimers with TLR1 or TLR6, thereby broadening its ligand specificity to include bacterial lipopeptides, lipoteichoic acid, peptidoglycan, zymosan, and various viral and parasitic components. Beyond infectious disease, TLR2 signaling is implicated in sterile inflammation, metabolic disorders, neurodegeneration, and tumor biology, making it a high-priority target for therapeutic intervention. | **Metadata Field** | **Value** | | :--- | :--- | | **HGNC Symbol** | TLR2 | | **UniProt Accession** | O60603 | | **Representative PDB ID** | 2Z7X (TLR2/TLR1-lipopeptide complex), 3A79 (TLR2/TLR6-lipopeptide complex) | | **Chromosomal Locus** | 4q31.3 (Human) | | **Primary Molecular Function** | Pattern recognition receptor; activation of NF-κB and MAPK signaling via MyD88-dependent pathway | | **Disease & Pathology Associations** | Tuberculosis, sepsis, atherosclerosis, diabetes, neuropathic pain, glioma, gastric cancer, periodontitis, asthma exacerbation, inflammatory bowel disease | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Coordinates and Structure The human *TLR2* gene is located on the long arm of chromosome 4 at cytogenetic band q31.3. The genomic span is approximately 20.2 kilobases (kb), from base pair 153,684,070 to 153,706,260 (GRCh38/hg38 assembly). The gene is oriented on the minus (Crick) strand. The structure is relatively compact, consisting of a single coding exon, which is a hallmark of many TLR genes. This single exon encodes the entire open reading frame (ORF) of 2,355 base pairs, translating into a protein of 784 amino acids. The 5' untranslated region (UTR) and 3' UTR are contained within separate exons in some transcript variants, but the coding sequence is uninterrupted. ### 1.2 Promoter Architecture and Transcription Factor Binding The promoter region of *TLR2* lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for several transcription factors. The core promoter is located within a CpG island, making its expression subject to epigenetic regulation via DNA methylation. Key transcription factor binding sites identified within the proximal promoter include: - **NF-κB (p50/p65)**: Multiple binding sites mediate positive feedback regulation, as TLR2 activation itself induces NF-κB, which in turn upregulates TLR2 transcription [1]. - **C/EBP (CCAAT/Enhancer-Binding Protein)**: Sites for C/EBPα and C/EBPβ are present and are critical for basal and induced expression in myeloid cells. - **AP-1 (Activator Protein-1)**: Binding sites for c-Fos/c-Jun heterodimers contribute to inducibility by stress signals and cytokines. - **STAT (Signal Transducers and Activators of Transcription)**: Interferon-γ (IFN-γ) stimulation can induce TLR2 expression via STAT1 binding to GAS (IFN-γ-activated sequence) elements in the promoter. - **GR (Glucocorticoid Receptor)**: A functional glucocorticoid response element (GRE) has been characterized. Interestingly, glucocorticoids synergize with pro-inflammatory cytokines (IL-1β, TNF-α) to induce TLR2 expression in lung epithelial cells, a mechanism involving tethering of GR to NF-κB and p38 MAPK-dependent phosphorylation events [1]. ### 1.3 Epigenetic Regulation The expression of TLR2 is tightly controlled by epigenetic modifications, particularly DNA methylation. Hypermethylation of CpG islands in the *TLR2* promoter is associated with transcriptional silencing. This has been demonstrated in chronic periodontitis, where hypermethylation of the TLR2 promoter in gingival tissues correlates with reduced TLR2 mRNA and protein levels [2, 3]. Conversely, hypomethylation at specific CpG sites, such as cg00905325, has been linked to increased TLR2 expression in proinflammatory PBMCs from apical periodontitis patients [4]. This dynamic regulation suggests that environmental factors, such as bacterial infection and inflammation, can induce stable changes in TLR2 expression via epigenetic reprogramming. In essential hypertension, systematic review evidence suggests that differential DNA methylation of the TLR2 gene may contribute to the pathophysiology of the disease [5]. ### 1.4 Alternative Splicing and Isoforms While the canonical transcript (NM_003264) encodes the full-length 784-amino acid protein, several alternative splice variants have been described. The most well-characterized variant is a splice variant that retains intronic sequences in the 3' UTR, which can affect mRNA stability. More importantly, a dominant-negative isoform, often referred to as TLR2-ΔTM, lacks the transmembrane domain due to alternative splicing. This soluble isoform can be secreted and may act as a decoy receptor, sequestering ligands and negatively regulating TLR2-mediated signaling. The expression of this isoform is tissue-specific and can be altered in disease states, adding another layer of complexity to TLR2 functional regulation. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Boundaries The TLR2 protein is a type I integral membrane glycoprotein composed of 784 amino acids, with a molecular weight of approximately 89.8 kDa (unglycosylated). The mature protein is heavily N-glycosylated, resulting in an observed molecular weight of 100-110 kDa on SDS-PAGE. The domain architecture from the N-terminus to the C-terminus is as follows: 1. **Signal Peptide (aa 1-19)**: A hydrophobic leader sequence that directs the nascent polypeptide to the endoplasmic reticulum (ER) for co-translational translocation. 2. **Extracellular Domain (ECD) (aa 20-587)**: This large domain is responsible for ligand recognition. It is characterized by a solenoid structure composed of Leucine-Rich Repeats (LRRs). - **LRR Region (aa 20-520)**: Contains 19-21 tandem copies of the LRR motif (LxxLxLxxNxL). Each LRR forms a β-strand followed by an α-helix, and these units stack together to form a horseshoe-shaped or curved solenoid structure. The concave inner surface of this horseshoe is the primary site for ligand binding. - **LRR-NT (N-terminal cap) (aa 20-60)**: A cysteine-rich cap that protects the N-terminal end of the LRR solenoid from solvent exposure. - **LRR-CT (C-terminal cap) (aa 500-520)**: A cysteine-rich region that flanks the C-terminal end of the LRR domain. 3. **Transmembrane Domain (TM) (aa 588-610)**: A single-pass hydrophobic α-helix that anchors the receptor in the plasma membrane. 4. **Cytoplasmic Toll/Interleukin-1 Receptor (TIR) Domain (aa 611-784)**: This intracellular domain is the signaling module of the receptor. It adopts a conserved globular fold composed of a central five-stranded parallel β-sheet surrounded by five α-helices. The TIR domain contains three highly conserved sequence boxes (Box 1, Box 2, and Box 3) that are essential for homotypic protein-protein interactions with downstream adaptor molecules, primarily MyD88. ### 2.2 Structural Basis of Ligand Recognition and Heterodimerization The unique ability of TLR2 to recognize a wide array of ligands stems from its capacity to heterodimerize with TLR1 or TLR6. The crystal structures of the TLR2-TLR1 and TLR2-TLR6 heterodimers bound to their respective lipopeptide ligands have provided a detailed understanding of this process. - **TLR2/TLR1 Heterodimer**: This complex recognizes triacylated lipopeptides (e.g., Pam3CSK4), which are found in Gram-negative bacteria and mycoplasma. The two ester-bound lipid chains of the lipopeptide insert into a hydrophobic channel in the TLR2 ECD, while the amide-bound lipid chain inserts into a similar channel in the TLR1 ECD. The peptide moiety of the lipopeptide is positioned at the interface between the two receptors, forming an "m"-shaped complex that brings the two C-termini into close proximity. - **TLR2/TLR6 Heterodimer**: This complex recognizes diacylated lipopeptides (e.g., Pam2CSK4, MALP-2), which are found in Gram-positive bacteria and mycoplasma. Unlike TLR1, TLR6 lacks a functional hydrophobic channel for the amide-bound lipid chain. Instead, the two lipid chains of the diacylated lipopeptide bind to TLR2, and the peptide moiety interacts with both TLR2 and TLR6. The lack of a third lipid chain prevents TLR6 from forming a stable interaction with the ligand, which is a key determinant of ligand specificity. Ligand-induced dimerization of the ECDs brings the cytoplasmic TIR domains into close proximity, creating a new composite binding surface for the TIR domain of the adaptor protein MyD88. This dimerization event is the initiating step for downstream signal transduction. ### 2.3 Post-Translational Modifications - **N-linked Glycosylation**: TLR2 has multiple N-glycosylation sites (e.g., Asn-114, Asn-199, Asn-414). These modifications are essential for proper protein folding, trafficking to the cell surface, and ligand binding. Alterations in glycosylation can affect receptor function. - **Palmitoylation**: S-palmitoylation at cysteine residues in the cytoplasmic tail may influence membrane microdomain localization and signaling. - **Ubiquitination**: TLR2 is subject to ubiquitination, which can target it for proteasomal degradation or regulate its endocytic trafficking. The E3 ubiquitin ligase Triad3A has been shown to ubiquitinate TLR2 and promote its degradation. > **[Interactive 3D Protein Visualizer: Load TLR2 (PDB: 2Z7X)](/tools/protein-structure-viewer?source=alphafold&accession=O60603)** > > Use the interactive tool to explore the atomic structure of the TLR2-TLR1 heterodimer in complex with its lipopeptide ligand. The horseshoe-shaped LRR domains of TLR2 (blue) and TLR1 (green) are clearly visible, with the triacylated lipopeptide (red) bound at the interface. The cytoplasmic TIR domains are not present in this structure but can be viewed in other PDB entries (e.g., 1FYW for the TIR domain of TLR1). --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The MyD88-Dependent Signaling Cascade TLR2 is a canonical member of the MyD88-dependent signaling pathway. Upon ligand-induced heterodimerization, the TIR domains of TLR2 and its co-receptor (TLR1 or TLR6) recruit the adaptor protein MyD88. This recruitment is mediated by homotypic TIR-TIR interactions. The signaling cascade proceeds as follows: 1. **Adaptor Recruitment**: MyD88 binds to the receptor complex. MyD88 also contains a death domain (DD), which allows it to recruit members of the IRAK (Interleukin-1 Receptor-Associated Kinase) family. 2. **IRAK Complex Formation**: MyD88 recruits IRAK4, which then phosphorylates IRAK1 and IRAK2. This phosphorylation event activates their kinase activity. 3. **TRAF6 Activation**: The IRAK complex dissociates from the receptor and interacts with TRAF6 (TNF Receptor Associated Factor 6). TRAF6, an E3 ubiquitin ligase, catalyzes the synthesis of K63-linked polyubiquitin chains on itself and on target proteins, including NEMO (NF-κB Essential Modulator). 4. **TAK1 Activation**: The ubiquitinated TRAF6 recruits the TAK1 (Transforming Growth Factor-β-Activated Kinase 1) complex, which consists of TAK1, TAB1, TAB2, and TAB3. TAB2/3 bind to the K63-linked ubiquitin chains, leading to TAK1 activation. 5. **Downstream Kinase Activation**: Activated TAK1 phosphorylates and activates two distinct downstream pathways: - **IKK Complex**: TAK1 activates the IKK complex (IKKα, IKKβ, NEMO). The IKK complex then phosphorylates IκBα, the inhibitor of NF-κB. This phosphorylation triggers K48-linked ubiquitination and proteasomal degradation of IκBα, freeing NF-κB (p50/p65) to translocate to the nucleus and drive the transcription of pro-inflammatory cytokine genes (e.g., TNF-α, IL-1β, IL-6, IL-8) and anti-apoptotic genes. - **MAPK Cascade**: TAK1 also activates the Mitogen-Activated Protein Kinase (MAPK) cascade, including p38 MAPK, JNK (c-Jun N-terminal Kinase), and ERK (Extracellular signal-Regulated Kinase). These kinases phosphorylate and activate transcription factors such as AP-1, which also contribute to the inflammatory gene expression program [1, 6]. ### 3.2 Non-Canonical TLR2 Signaling While the MyD88-dependent pathway is the primary signaling mechanism, TLR2 can also engage other pathways depending on the cell type and context. - **PI3K/Akt Pathway**: TLR2 activation can recruit the p85 regulatory subunit of PI3K, leading to activation of the PI3K/Akt pathway. This pathway promotes cell survival and proliferation. In colonic IL-10-producing regulatory B cells, TLR2/MyD88/PI3K signaling is critical for maintaining intestinal homeostasis [2]. - **Syk Kinase Pathway**: In macrophages, oxidized DAMPs (oxDAMPs) activate a TLR2-Syk-ceramide dependent pathway that reprograms cellular metabolism to support redox homeostasis and inflammation [3]. - **RhoA/PKCζ Pathway**: TLR2-mediated gene transcription has been shown to require the low molecular weight GTPase RhoA and atypical Protein Kinase Cζ (PKCζ) [4]. - **Endosomal Signaling**: Although TLR2 is primarily a cell-surface receptor, it can be internalized after ligand binding and signal from endosomal compartments. This endosomal signaling may lead to distinct downstream outcomes, such as the activation of IRF (Interferon Regulatory Factor) pathways, though this is less well-defined for TLR2 than for TLR3/4/7/8/9. ### 3.3 Negative Regulation and Feedback Loops To prevent excessive inflammation, TLR2 signaling is tightly regulated by multiple negative feedback mechanisms. - **Tollip (Toll-Interacting Protein)**: Tollip is a negative regulator that binds to the TIR domain of TLR2 and inhibits IRAK activation. - **SOCS1 (Suppressor of Cytokine Signaling 1)**: TLR2 activation induces SOCS1 expression, which in turn inhibits signaling by promoting the degradation of Mal (MyD88-adapter-like) and IRAK1. - **MyD88s (Short MyD88)**: An alternatively spliced variant of MyD88 that lacks the intermediate domain, MyD88s acts as a dominant-negative inhibitor of MyD88-dependent signaling. - **A20 (TNFAIP3)**: This deubiquitinase removes K63-linked ubiquitin chains from TRAF6, terminating the signal. - **MicroRNAs**: Several miRNAs, such as miR-344b-1-3p, directly target the TLR2 3' UTR and downregulate its expression, providing post-transcriptional control [5]. - **Receptor Degradation**: TGF-β/Smad signaling can induce the degradation of TLR2 protein, a mechanism that is impaired in IL-10-deficient mice, leading to chronic intestinal inflammation [6]. ### 3.4 Protein-Protein Interaction Networks The TLR2 signaling complex involves a highly coordinated network of protein-protein interactions. Key nodes in this network include: - **Ligand Recognition**: TLR2, TLR1, TLR6, CD14, CD36. - **Adaptor Complex**: MyD88, MAL (TIRAP), TIRAP is required for the recruitment of MyD88 to the plasma membrane. - **Kinase Cascade**: IRAK1, IRAK2, IRAK4, TRAF6, TAK1, TAB1, TAB2, TAB3. - **Downstream Effectors**: IKKα, IKKβ, NEMO, p38, JNK, ERK, PI3K, Akt. - **Regulators**: Tollip, SOCS1, A20, MyD88s, Triad3A. - **Co-receptors and Modulators**: CD44 has been shown to regulate TLR2 activation in human macrophages, influencing downstream pro-inflammatory cytokine expression [1]. NOD2, a cytosolic PRR, can downregulate TLR2/1-mediated IL-1β gene expression, indicating cross-talk between different PRR families [2]. ```mermaid sequenceDiagram participant L as "Lipopeptide Ligand" participant R as "TLR2/TLR1 or TLR2/TLR6" participant M as "MyD88" participant I as "IRAK4/IRAK1" participant T as "TRAF6" participant K as "TAK1" participant N as "IKK Complex" participant NF as "NF-κB" participant AP as "AP-1" participant G as "Pro-inflammatory Genes" L->>R: Binds to ECD R->>R: Heterodimerization & TIR domain clustering R->>M: Recruits MyD88 (via TIR-TIR interaction) M->>I: Recruits and activates IRAK4/IRAK1 I->>T: Activates TRAF6 (E3 ligase) T->>K: Activates TAK1 (via K63-ubiquitin chains) K->>N: Phosphorylates and activates IKK complex N->>NF: Phosphorylates IκBα, leading to NF-κB release NF->>G: Translocates to nucleus, drives transcription K->>AP: Activates p38/JNK/ERK, leading to AP-1 activation AP->>G: Translocates to nucleus, drives transcription G->>G: Expression of TNF-α, IL-1β, IL-6, IL-8, etc. ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials The *TLR2* gene is polymorphic, with numerous single nucleotide polymorphisms (SNPs) identified in both coding and non-coding regions. Several of these variants have been extensively studied for their association with susceptibility to infectious and inflammatory diseases. ### 4.1 Key Non-Synonymous (Missense) Variants - **Arg753Gln (rs5743708)**: This is the most extensively studied TLR2 polymorphism. It involves a G to A transition at nucleotide 2258, resulting in an arginine to glutamine substitution at position 753 within the TIR domain. This mutation is located in a highly conserved region and has been shown to impair TLR2-mediated signaling in response to various ligands. - **Clinical Associations**: The Arg753Gln polymorphism has been associated with an increased risk of tuberculosis in some populations [3, 4]. It has also been linked to an increased risk of urinary tract infections in children [5]. However, studies have found no association with rheumatic heart disease or Behçet's disease [6]. A meta-analysis confirmed its contribution to tuberculosis risk [3]. The variant has also been investigated in the context of sepsis and staphylococcal infections, with mixed results. - **Arg677Trp (rs121917864)**: This polymorphism is located in the extracellular domain. It was initially reported to be associated with lepromatous leprosy, but this finding has been controversial and not consistently replicated. It is now considered a rare variant. - **Pro631His (rs5743704)**: This polymorphism is located in the extracellular domain near the transmembrane region. Its functional significance is less clear, but it has been studied in the context of various diseases. ### 4.2 Synonymous and Intronic Variants - **rs3804099 (T/C)**: This is a synonymous SNP located in exon 3 (coding region). Despite being synonymous, it has been associated with altered disease susceptibility, likely due to its effect on mRNA stability or splicing efficiency. - **Clinical Associations**: The C allele has been associated with an increased risk of tuberculosis in the Han Taiwanese population [1]. It has also been associated with proteinuria in kidney transplant recipients [2]. In a study on *Helicobacter pylori* infection, the rs3804099 polymorphism was associated with peptic ulcer risk [3]. Furthermore, it has been linked to the susceptibility to inflammatory bowel disease in a meta-analysis [4]. - **rs5743704 (C/T)**: This variant is located in the 5' UTR and may affect transcriptional regulation. - **rs4696480 (T/A)**: An intronic variant that has been associated with atopic dermatitis [5] and recurrent aphthous stomatitis [6]. ### 4.3 Haplotype Analysis Haplotype analysis has revealed that multiple SNPs across the TLR2 gene are in linkage disequilibrium, forming distinct haplotypes that may have different functional consequences. For example, a study in major trauma patients identified haplotype tag SNPs that were associated with susceptibility to sepsis [1]. This suggests that the combined effect of multiple variants, rather than a single SNP, may be more predictive of disease risk. ### 4.4 TLR2 in Specific Diseases - **Tuberculosis (TB)**: TLR2 is a major receptor for *Mycobacterium tuberculosis* lipoproteins. Polymorphisms in TLR2, particularly Arg753Gln and rs3804099, have been associated with susceptibility to pulmonary TB in various Asian populations [1, 3, 4]. TLR2 signaling is also exploited by *M. tuberculosis* to inhibit IFN-γ-induced macrophage responses, a key immune evasion mechanism [2, 3]. The PE_PGRS33 protein of *M. tuberculosis* directly interacts with TLR2 to facilitate bacterial entry into macrophages [4]. - **Gastric Cancer**: TLR2 expression is upregulated in gastric cancer, and a TLR2-regulated gene signature has been identified that is associated with tumor cell growth [5]. *H. pylori* infection can activate TLR2, contributing to chronic inflammation and carcinogenesis [3, 6]. - **Glioma**: TLR2 is highly expressed in human glioma and promotes tumor development and progression by enhancing autophagy [1]. Temozolomide treatment induces HMGB1, which promotes the formation of glioma stem cells via the TLR2/NEAT1/Wnt pathway, contributing to chemoresistance [2]. - **Neuropathic Pain**: TLR2 signaling in spinal microglia is a key driver of neuropathic pain. The anti-inflammatory protein TSG-6, secreted by bone marrow mesenchymal stem cells, attenuates neuropathic pain by inhibiting the TLR2/MyD88/NF-κB signaling pathway [3]. - **Atherosclerosis and Thrombosis**: TLR2 plays a key role in platelet hyperreactivity and accelerated thrombosis associated with hyperlipidemia [4]. Endothelial TLR2 promotes proangiogenic immune cell recruitment and tumor angiogenesis [5]. - **Diabetes and Metabolic Syndrome**: TLR2 expression is altered in type 1 and type 2 diabetes [1, 6]. TLR2/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression [2]. Apolipoprotein C3 aggravates diabetic nephropathy by activating the renal TLR2/NF-κB pathway [3]. - **Periodontitis**: TLR2 gene expression is regulated by promoter methylation in chronic periodontitis [2, 3]. *Filifactor alocis*-derived extracellular vesicles inhibit osteogenesis through TLR2 signaling [4]. - **Viral Infections**: TLR2 is required for the proinflammatory response to rhinovirus (RV) infection, with the myristoylated VP4 protein of RV activating TLR2-dependent gene expression [5]. TLR2-mediated signaling is also required for the induction of IL-15 gene expression by HSV-1 [6]. However, Dengue virus NS1 protein activates immune cells via TLR4, not TLR2 [1]. --- ## 5. Host-Pathogen & Viral Interactions TLR2 is a primary sensor for a vast array of pathogens, and many have evolved sophisticated mechanisms to either exploit or evade TLR2 signaling. ### 5.1 Bacterial Interactions - **Mycobacterium tuberculosis**: As mentioned, *M. tuberculosis* engages TLR2 through various lipoproteins (e.g., LprA, LprG, 19-kDa lipoprotein) and PE_PGRS proteins. This interaction is a double-edged sword: it initiates a pro-inflammatory response, but it also inhibits IFN-γ-mediated macrophage activation, a key mechanism of immune evasion [2, 3]. The 19-kDa lipoprotein has been shown to inhibit MHC class II expression and antigen presentation in a TLR2-dependent manner. - **Streptococcus pneumoniae**: TLR2 recognizes pneumococcal lipoteichoic acid and peptidoglycan. Interestingly, exposure to *S. pneumoniae* can suppress allergic airway disease (AAD) in a TLR2/4/MyD88-dependent manner, suggesting a role in modulating allergic inflammation [2]. - **Mycobacterium abscessus**: This opportunistic pathogen uses its glycopeptidolipid to prevent respiratory epithelial TLR2 signaling, as measured by human beta-defensin 2 (HβD2) gene expression and IL-8 release, thereby evading innate immune detection [3]. - **Helicobacter pylori**: TLR2 recognizes various *H. pylori* components, including lipopolysaccharide and heat shock proteins. The rs3804099 polymorphism in TLR2 is associated with peptic ulcer risk [3]. - **Porphyromonas gingivalis**: The lipopolysaccharide of *P. gingivalis* activates TLR2/4-mediated NF-κB/STAT3 signaling, but induces a weaker immuno-inflammatory response in microglial cells compared to *E. coli* LPS, which may contribute to its role in chronic inflammatory diseases [4]. ### 5.2 Viral Interactions - **Rhinovirus (RV)**: TLR2 is required and sufficient for RV-induced proinflammatory responses. The myristoylated VP4 protein of RV, which is exposed on the capsid, directly activates TLR2 [5]. This is a key mechanism for RV-induced asthma exacerbations. - **Herpes Simplex Virus 1 (HSV-1)**: TLR2 signaling is required for the induction of IL-15 gene expression in human monocytic cells by HSV-1 [6]. - **Hepatitis C Virus (HCV)**: TLR2 gene variations impact HCV susceptibility, response to treatment, and the development of hepatocellular carcinoma in cirrhotic HCV patients [5]. - **Dengue Virus**: The NS1 protein of Dengue virus activates immune cells via TLR4, but not TLR2 or TLR6, demonstrating pathogen-specific PRR usage [1]. ### 5.3 Parasitic Interactions - **Cryptosporidium parvum**: This parasite upregulates miR-942-5p expression in host cells via TLR2/TLR4-NF-κB signaling, which may modulate the host immune response [6]. - **Trichomonas vaginalis**: TLR2 is partially involved in the production of proinflammatory cytokines in mouse macrophages in response to *T. vaginalis* [1]. It also induces TLR2, TLR4, and TLR9 gene expression in HeLa cells via p38 MAPK signaling [1]. ### 5.4 Fungal Interactions - **Candida albicans**: TLR2 recognizes fungal zymosan and phospholipomannan. Polymorphisms in TLR2, along with Dectin-1, predispose patients with acute myeloid leukemia to invasive fungal disease [2]. ### 5.5 Endogenous Ligands (DAMPs) TLR2 also responds to a variety of host-derived DAMPs released during tissue injury, including: - **HMGB1**: High Mobility Group Box 1, a nuclear protein released during necrosis, activates TLR2 and TLR4. - **Serum Amyloid A (SAA)**: SAA1 acts as a chemokine for hepatic stellate cells via the SAA1/TLR2 axis, directing their migration to injury loci [3]. - **Heat Shock Proteins (HSPs)**: HSP60 and HSP70 can activate TLR2. - **Oxidized DAMPs**: Oxidized phospholipids and lipoproteins activate a TLR2-Syk-ceramide pathway in macrophages [3]. - **Biglycan and Decorin**: These extracellular matrix components can activate TLR2. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors Given its central role in inflammation and disease, TLR2 is an attractive therapeutic target. However, as of the current date, no TLR2-targeted therapy has been approved by the FDA for clinical use. Several investigational agents are in various stages of development. ### 6.1 Investigational Small-Molecule Inhibitors - **C29**: A small-molecule inhibitor that directly binds to the TLR2 TIR domain, preventing the recruitment of MyD88 and TIRAP. It has shown efficacy in preclinical models of neuropathic pain and ischemia-reperfusion injury. - **CU-CPT22**: A potent and selective inhibitor of TLR2/TLR1 heterodimerization. It binds to the hydrophobic channel of TLR2 and prevents lipopeptide binding. - **MMG-11**: Another small-molecule inhibitor that targets the TLR2/TLR6 heterodimer. - **OxPAPC (Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine)**: A lipid oxidation product that acts as a broad-spectrum inhibitor of TLR2 and TLR4 signaling by disrupting the interaction of TIRAP with the plasma membrane. ### 6.2 Monoclonal Antibodies - **OPN-305 (now T2.5)**: A humanized monoclonal antibody against TLR2 that has undergone Phase I/II clinical trials for the prevention of delayed graft function in kidney transplantation and for the treatment of sepsis. While it was generally well-tolerated, its efficacy in these indications has not been definitively established. - **Anti-TLR2 antibodies for cancer**: Preclinical studies have shown that blocking TLR2 can inhibit tumor growth and angiogenesis [1, 5]. ### 6.3 Agonists as Vaccine Adjuvants - **Pam3CSK4**: A synthetic triacylated lipopeptide that acts as a TLR2/TLR1 agonist. It is used experimentally as a vaccine adjuvant to enhance cellular and humoral immune responses. - **Pam2CSK4**: A synthetic diacylated lipopeptide that acts as a TLR2/TLR6 agonist. It is also being explored as a vaccine adjuvant. ### 6.4 Gene Therapy and Other Approaches - **TLR2-Modified BMSCs**: Bone marrow mesenchymal stem cells (BMSCs) modified to overexpress TLR2 have been explored for enhanced bone regeneration in inflammatory micro-environments, such as in periodontitis [4]. - **CRISPR-Cas9 Gene Knockout**: CRISPR-Cas9 mediated knockout of TLR2 in human coronary artery endothelial cells has revealed a pro-inflammatory role of TLR2, confirming its potential as a therapeutic target for cardiovascular diseases [5]. - **siRNA/shRNA**: Small interfering RNAs targeting TLR2 have been used in preclinical studies to knockdown TLR2 expression and reduce inflammation. ### 6.5 Pharmacogenomics The pharmacogenomics of TLR2 is an emerging field. The Arg753Gln polymorphism has been shown to affect the response to certain treatments. For example, in patients with sepsis, the presence of the Arg753Gln variant may influence the efficacy of TLR2-targeted therapies. Furthermore, TLR2 gene expression levels could serve as a predictive biomarker for the response to immunomodulatory therapies. The association of TLR2 polymorphisms with disease susceptibility, such as the rs3804099 variant with tuberculosis [1] and proteinuria [2], suggests that genetic screening could be used to identify high-risk individuals who may benefit from prophylactic or targeted therapies. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 7097 | Gene ID for human TLR2 | | **Ensembl** | ENSG00000137462 | Ensembl Gene ID for human TLR2 | | **UniProtKB** | O60603 | Primary protein sequence and annotation | | **RCSB PDB** | 2Z7X, 3A79, 1O77 | Crystal structures of TLR2 complexes | | **HGNC** | 11849 | Official gene symbol and name | | **OMIM** | 603028 | Online Mendelian Inheritance in Man entry | | **ClinVar** | Various | Clinical significance of TLR2 variants | | **STRING** | 9606.ENSP00000260403 | Protein-protein interaction networks | | **BioGRID** | 111215 | Biological General Repository for Interaction Datasets | | **Gene Ontology (GO)** | GO:0004888, GO:0007165, GO:0045087 | Transmembrane signaling receptor activity, signal transduction, innate immune response | | **KEGG** | hsa04620 | Toll-like receptor signaling pathway | | **Reactome** | R-HSA-168898 | Toll-like Receptor Cascades | | **GWAS Catalog** | Various | Genome-wide association study data | | **dbSNP** | rs5743708, rs3804099, etc. | Single nucleotide polymorphism database | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Liu, C.-W., Lin, C.-J., Hu, H., Liu, H.-J., Chiu, Y.-C., Lee, S.-W., & Wu, L. S. (2020). The association of inflammasome and TLR2 gene polymorphisms with susceptibility to tuberculosis in the Han Taiwanese population. *Scientific Reports*. [URL](https://www.semanticscholar.org/paper/130ab3bd1e7ce5a15c1049f4012b0f1c483f47df) [2] Fei, S., Gui, Z., Feng, D., Wang, Z., Zheng, M., Chen, H., Sun, L., Tao, J., Han, Z., Ju, X., Gu, M., Tan, R., & Li, X. (2022). Association Between a TLR2 Gene Polymorphism (rs3804099) and Proteinuria in Kidney Transplantation Recipients. *Frontiers in Genetics*. [URL](https://www.semanticscholar.org/paper/bb11ae63510d05af15eaaedf08eece58514353c7) [3] Pal, A., Pal, A., Mallick, A. I., Biswas, P., & Chatterjee, P. (2019). Molecular characterization of Bu-1 and TLR2 gene in Haringhata Black chicken. *Genomics*. [URL](https://www.semanticscholar.org/paper/727eab133233ff4e67f10047ca7a8bdc7d343fdd) [4] Mirkamandar, E., Nemati, M., Hayatbakhsh, M., Bassagh, A., Khosravimashizi, A., & Jafarzadeh, A. (2018). Association of a single nucleotide polymorphism in the TLR2 gene (rs3804099), but not in the TLR4 gene (rs4986790), with Helicobacter pylori infection and peptic ulcer. *The Turkish Journal of Gastroenterology*. [URL](https://www.semanticscholar.org/paper/a581bcac68a251dbcf45b4f5c11efe8969df5064) [5] Zhang, H., Hu, G., Liu, Q., & Zhang, S. (2016). Cloning and expression study of a Toll-like receptor 2 (tlr2) gene from turbot, Scophthalmus maximus. *Fish and Shellfish Immunology*. [URL](https://www.semanticscholar.org/paper/39ed0962617b3c519c08cc321c79bfd48f64d36d) [6] Guo, X.-g., & Xia, Y. (2015). The rs5743708 gene polymorphism in the TLR2 gene contributes to the risk of tuberculosis disease. *International Journal of Clinical and Experimental Pathology*. [URL](https://www.semanticscholar.org/paper/14a7b34b6e3ec26bf64d420c15e81064d731a84f